Hey Cabel...
The post noretreat referenced is at agoracom.com in the resverlogix forum, posted june 21 if memory serves by a user with the name tundup (going off memory here).
As for your belief that $20 is doable, I agree...although I'm thinking $10 by EOY has a good chance, with $20 sometime next year if everything goes right.
There's so much that can happen though...even if the trial achieves great results in primary and secondary outcomes....there's the business side.
Resverlogix just engaged Rothschild & Co with respect to seeking a US listing. I've seen other CDN companies get listings on the NAZ, Stellar Biotech springs immediately to mind...and they didn't engage an advisor of the stature of Rothschild. In point of fact I don't think they engaged any advisors with respect to their uplisting. They did hire some outfit called Huft or something like that for corporate communications (IR promo imo).
It has me thinking there may be something bigger in the cards than a simple listing on the Nasdaq.
Chinese Pharma Co Shenzhen Hepalink owns something like 43% of Resverlogix already, they're the world's largest producer of Heparin Sodium according to the independent analyst report put out by Beacon's Dr. David Kideckle, a man who by the way has both a PHD in neursciences AND an MBA if memory serves.
Hepalink is a publicly traded company, but only in China on the Shenzhen stock exchange. I can't help but speculate that there may be M&A type discussions going on that would result in Hepalink using its large ownership position to gain entry to the US market....
Fun times in any case, I can see a variety of ways things could play out, ways that are all positive for shareholders.
If you want to taste the fruit, you have to go out on a limb. But if you wait for the herd to move out on the limb....the branch tends to snap.
